These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2533661)

  • 1. [Therapeutic use of a peptide fraction derived from bovine factor VIII in epistaxis in children].
    Tarantino V; Stura M; Cingolani M
    Minerva Pediatr; 1989 Nov; 41(11):549-51. PubMed ID: 2533661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reduction of intra- and post-operative bleeding after treatment with a peptide fraction derived from bovine factor VIII].
    Tarantino V; Cingolani M; Benzi L; Fortini P
    Pediatr Med Chir; 1989; 11(6):703-6. PubMed ID: 2517640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, single-blind, randomized controlled trial of petroleum jelly/Vaseline for recurrent paediatric epistaxis.
    Loughran S; Spinou E; Clement WA; Cathcart R; Kubba H; Geddes NK
    Clin Otolaryngol Allied Sci; 2004 Jun; 29(3):266-9. PubMed ID: 15142073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of bleeding time by a peptide fraction from bovine factor VIII in laboratory animals.
    Gervasi GB; Bartoli C; Carpita G; Baldacci M
    Arzneimittelforschung; 1988 Sep; 38(9):1268-70. PubMed ID: 3146984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of a new factor VIII concentrate in hemophilic children].
    Carnelli V; Cultrera S; Simoni L; Pasqui G; Busso B; Bagnato L
    Pediatr Med Chir; 1983; 5(3):49-55. PubMed ID: 6417627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A pharmacological and clinical review on the activity of a bovine factor VIII derivative obtained by enzymatic hydrolysis].
    Ammannati P; Siravo D; Conte B
    Clin Ter; 1989 Feb; 128(4):271-90. PubMed ID: 2524317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against marked plasma leakage in dengue haemorrhagic fever by infusion of carbazochrome sodium sulfonate (AC-17).
    Funahara Y; Sumarmo ; Shirahata A; Harun SR; Setiabudy-Dharma R; Nathin MA; Karjomanggolo TW; Tamaela LA
    Southeast Asian J Trop Med Public Health; 1987 Sep; 18(3):356-61. PubMed ID: 2963380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral troxerutin and carbazochrome combination in the treatment of post-hemorrhoidectomy status: a randomized, double-blind, placebo-controlled, phase IV study.
    Basile M; Gidaro S; Pacella M; Biffignandi PM; Gidaro GS
    Curr Med Res Opin; 2001; 17(4):256-61. PubMed ID: 11922398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis.
    Mathiasen RA; Cruz RM
    Laryngoscope; 2005 May; 115(5):899-902. PubMed ID: 15867662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inhibitor of antihemophilic factor (factor VIII) in an 18-month-old nonhemophilic child.
    Stein J; Ratnoff OD
    Am J Pediatr Hematol Oncol; 1993 Aug; 15(3):346-50. PubMed ID: 8328652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of sodium carbazochrome sulfonate in latent purpura of hypertensive subjects].
    Barbera C; Bianco C; Guerrisi O; Consolo F
    Clin Ter; 1976 Oct; 79(2):111-20. PubMed ID: 138499
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effect of dipyridamole in patients with IgA nephropathy.
    Yagame M; Tomino Y; Miura M; Suga T; Endoh M; Nomoto Y; Sakai H
    Tokai J Exp Clin Med; 1986 Nov; 11(5):329-33. PubMed ID: 2960035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 17. The management of bleeding in hemophilia.
    Abildgaard CF
    Adv Pediatr; 1969; 16():365-90. PubMed ID: 4899062
    [No Abstract]   [Full Text] [Related]  

  • 18. Double-blind, randomized clinical trial of troxerutin-carbazochrome in patients with hemorrhoids.
    Squadrito F; Altavilla D; Oliaro Bosso S
    Eur Rev Med Pharmacol Sci; 2000; 4(1-2):21-4. PubMed ID: 11409185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An old drug for a new application: carbazochrome-sodium-sulfonate in HHT.
    Passali GC; De Corso E; Bastanza G; Di Gennaro L;
    J Clin Pharmacol; 2015 May; 55(5):601-2. PubMed ID: 25644784
    [No Abstract]   [Full Text] [Related]  

  • 20. Recurrent idiopathic epistaxis (nosebleeds).
    McGarry G
    Clin Evid; 2002 Jun; (7):349-51. PubMed ID: 12230659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.